> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Beovu
- URL: https://www.fdaweb.com/regulatory-review-period-for-beovu/
- Published: 2021-07-07T12:00:00.000Z
- Updated: 2026-09-14T17:05:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149650

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Novartis’ Beovu (brolucizumab-dbll), indicated for treating neovascular (wet) age-related macular degeneration. The regulatory review period is 3,064 days, which includes 2,821 days that occurred during the testing phase and 243 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14473.pdf?ref=fdaweb.com).